Eikon Therapeutics, Inc. (EIKN) Balance Sheet
EIKN balance sheet, 2025
December 31, 2025 · U.S. dollars$594.7M assets = $1.47B liabilities + −$879.0M equity
Liabilities exceed assets: shareholders’ equity is negative (−$879.0M).
Both columns are drawn to the same scale: what EIKN owns equals what it owes plus shareholders’ equity. Hover a block for its value.
EIKN financial health
Descriptive bands, not a rating. Fiscal 2025.
EIKN balance sheet trends, 2023–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $525.7M2023 | $594.7M2025 | +6.4%/yr | |
| Total liabilities | $867.1M2023 | $1.47B2025 | +30.4%/yr | |
| Shareholders’ equity | −$341.4M2023 | −$879.0M2025 | — | |
| Cash & short-term investments | $430.4M2023 | $336.0M2025 | −11.6%/yr | |
| Working capital | $405.0M2023 | $293.9M2025 | −$111.1M | |
| Book value per share | −$6.322023 | −$16.242025 | — | |
| Current ratio | 13.882023 | 6.342025 | −7.54 | |
| Shares outstanding | 54.0M2023 | 54.1M2025 | +0.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
EIKN assets
EIKN liabilities and equity
EIKN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
EIKN balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | $336.0M | $220.1M | $430.4M |
| Cash & equivalents | $104.9M | $129.2M | $112.8M |
| Short-term investments | $231.1M | $90.9M | $317.6M |
| Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other current assets | $12.9M | $7.8M | $6.0M |
| Total current assets | $348.9M | $227.9M | $436.4M |
| Property, plant & equipment (net) | $233.9M | $259.1M | $86.9M |
| Goodwill & intangible assets | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 |
| Other non-current assets | $12.0M | $4.2M | $2.4M |
| Total assets | $594.7M | $491.2M | $525.7M |
| Liabilities | |||
| Accounts payable | $681,000 | $17.6M | $2.2M |
| Short-term debt | $10.0M | — | — |
| Total current liabilities | $55.0M | $56.4M | $31.4M |
| Long-term debt | $0 | $0 | $0 |
| Lease obligations | $257.3M | $202.5M | $31.7M |
| Other long-term liabilities | $1.42B | $1.01B | $835.6M |
| Total liabilities | $1.47B | $1.06B | $867.1M |
| Shareholders' equity | |||
| Retained earnings (deficit) | −$920.5M | −$604.9M | −$361.1M |
| Total shareholders' equity | −$879.0M | −$571.9M | −$341.4M |
| Key figures | |||
| Total debt | $257.3M | — | — |
| Net cash (debt) | $78.7M | — | — |
| Working capital | $293.9M | $171.4M | $405.0M |
| Tangible book value | −$879.0M | −$571.9M | −$341.4M |
| Book value per share | −$16.24 | −$10.59 | −$6.32 |
| Shares outstanding | 54.1M | 54.0M | 54.0M |
| Current ratio | 6.34 | 4.04 | 13.88 |
| Quick ratio | 6.11 | 3.90 | 13.69 |
| Equity / assets | −147.8% | −116.4% | −64.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Dec '24 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $531.6M | $512.6M | $336.0M | $375.9M | $220.1M |
| Cash & equivalents | $143.0M | $161.6M | $104.9M | $104.9M | $129.2M |
| Short-term investments | $388.6M | $351.0M | $231.1M | $271.0M | $90.9M |
| Receivables | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $15.4M | $16.9M | $12.9M | $14.6M | $7.8M |
| Total current assets | $547.0M | $529.5M | $348.9M | $390.5M | $227.9M |
| Property, plant & equipment (net) | $224.2M | $229.1M | $233.9M | $241.2M | $259.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $83.8M | $0 | $0 | $0 |
| Other non-current assets | $8.4M | $8.4M | $12.0M | $10.7M | $4.2M |
| Total assets | $779.6M | $850.8M | $594.7M | $642.3M | $491.2M |
| Liabilities | |||||
| Accounts payable | $6.6M | $6.0M | $681,000 | $4.3M | $17.6M |
| Short-term debt | $9.4M | $9.7M | $10.0M | $9.9M | — |
| Total current liabilities | $55.3M | $45.1M | $55.0M | $44.4M | $56.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $252.2M | $254.8M | $257.3M | $240.7M | $202.5M |
| Other long-term liabilities | $257.8M | $255.1M | $1.42B | $1.40B | $1.01B |
| Total liabilities | $313.1M | $300.2M | $1.47B | $1.45B | $1.06B |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $5,000 | $5,000 | — | — | — |
| Retained earnings (deficit) | −$1.09B | −$1.00B | −$920.5M | −$840.9M | −$604.9M |
| Total shareholders' equity | $466.5M | $550.7M | −$879.0M | −$804.4M | −$571.9M |
| Key figures | |||||
| Total debt | $252.2M | $254.8M | $257.3M | $240.7M | — |
| Net cash (debt) | $279.4M | $257.8M | $78.7M | $135.1M | — |
| Working capital | $491.7M | $484.4M | $293.9M | $346.1M | $171.4M |
| Tangible book value | $466.5M | $550.7M | −$879.0M | −$804.4M | −$571.9M |
| Book value per share | $8.62 | $10.17 | −$16.24 | −$14.90 | −$10.59 |
| Shares outstanding | 54.1M | 54.1M | 54.1M | 54.0M | 54.0M |
| Current ratio | 9.89 | 11.75 | 6.34 | 8.80 | 4.04 |
| Quick ratio | 9.61 | 11.37 | 6.11 | 8.47 | 3.90 |
| Debt / equity | 0.54 | 0.46 | — | — | — |
| Equity / assets | 59.8% | 64.7% | −147.8% | −125.2% | −116.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
EIKN financial position
At the end of fiscal 2025 (December 31, 2025), Eikon Therapeutics had total assets of $594.7 million (up 21.1% from a year earlier), total liabilities of $1.5 billion and shareholders' equity of -$879.0 million. It held $336.0 million in cash and short-term investments against $257.3 million of debt, a net cash position of $78.7 million. Its current ratio was 6.34. In the latest quarter (ended June 30, 2026) total assets were $779.6 million and equity $466.5 million.
Related: EIKN income statement, EIKN cash flow statement, EIKN key metrics. See the EIKN stock overview for the latest quote and news.
EIKN balance sheet FAQ
What are Eikon Therapeutics's total assets?
Eikon Therapeutics reported total assets of $594.7 million at the end of fiscal 2025 (December 31, 2025), compared with $491.2 million a year earlier.
How much debt does Eikon Therapeutics have?
Eikon Therapeutics had $257.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Eikon Therapeutics have?
Eikon Therapeutics held $336.0 million in cash and short-term investments at the end of fiscal 2025; with $257.3 million of debt that is net cash of $78.7 million.
What is Eikon Therapeutics's book value?
Eikon Therapeutics's shareholders' equity (book value) was -$879.0 million at the end of fiscal 2025, or −$16.24 per share.
What is Eikon Therapeutics's current ratio?
Eikon Therapeutics had current assets of $348.9 million and current liabilities of $55.0 million, a current ratio of 6.34 (it can cover its short-term obligations).